6º BH RETINA SUMMIT
  1. Página Inicial

Programação

Centenário
13:30 - 13:35 Opening

Opening

Centenário
13:35 - 13:45 Opening

Bayer - Legacy of a decade in Brazil

Centenário
13:45 - 15:45 Rising Stars

Rising Stars - Bloco 1

13:45 - 13:51
Fundação Dr. João Penido Burnier
13:52 - 13:58
FAV- Fundação Altino Ventura
14:06 - 14:12
Hospital da Gamboa – RJ
14:13 - 14:19
COMG
14:20 - 14:26
USP
14:27 - 14:33
Hospital Banco de Olhos de Porto Alegre– RS
14:34 - 14:40
UFBA
14:41 - 14:47
UFMG
14:48 - 14:54
UNESP
14:55 - 15:01
Hospital de Olhos do Paraná
15:02 - 15:08
UFRS
15:16 - 15:22
Retina Clinic
15:23 - 15:29
UFF
15:30 - 15:36
CBV
15:37 - 15:43
Instituto Suel Abujamra
Centenário
15:45 - 16:15 Break

Break

Centenário
16:15 - 17:45 Rising Stars

Rising Stars - Bloco 2

16:15 - 16:21
UNICAMP
16:22 - 16:28
Hospital de Olhos Santa Luzia – PE
16:29 - 16:35
IOCM
16:36 - 16:42
Hospital dos Servidores do Estado – RJ
16:43 - 16:49
BOS Sorocaba
16:50 - 16:56
UNIFESP
16:57 - 17:03
Santa Casa – PR
17:04 - 17:10
USP Ribeirão Preto
17:11 - 17:17
Santa Casa – BH
17:18 - 17:24
Faculdade de Medicina do ABC
17:25 - 17:31
Fundação Banco de Olhos de Goiás
17:32 - 17:38
UFRJ
Centenário
17:45 - 19:00 Session

Retinal Science in Focus

17:45 - 17:50
Anormalidades Vasculares Retinianas após infecção após COVID-19 e vacinas.
17:50 - 17:55
Qualidade de vida, sensibilidade ao contraste e campo visual nos pacientes com doença de Vogt-Koyanagi-Harada.
17:55 - 18:00
Perfil Epidemiológico e Correlação Genótipo-Fenotípica das Distrofias Retinianas tipo Bastonetes-cones
18:00 - 18:05
Novos conceitos nos benefícios da Vitrectomia Precoce X Injecoes Intravitreas nas Endoftalmites: Análise retrospectiva de 9 anos e estudo prospectivo randomizado
18:05 - 18:10
Avaliação retiniana multimodal em pacientes assintomáticos com síndrome antifosfolípide secundária a lúpus eritematoso sistêmico
18:10 - 18:15
Analise sobre o uso da inteligencia artificial na identificação de alterações morfológicas e funcionais em resposta ao tratamento da DMRI neovascular em uma cohort de vida real.
18:15 - 18:20
Novos conceitos para se otimizar os resultados da cirurgia vitreorretiniana com o controle dos fatores externos relacionados a destreza e microtremor dos cirurgiões em diferentes níveis de experiência
18:20 - 18:25
Avaliação multimodal com uso de angiotomografia de coerência óptica em pacientes assintomáticos com síndrome antifosfolípide primária.
18:25 - 18:45
Discussão
Centenário
07:55 - 08:00 Opening

Opening

Centenário
08:00 - 09:00 Session

Diabetic retinopathy

08:00 - 08:08
Diabetic Macular Edema: update in DRCR.net
08:08 - 08:16
Faricimab in diabetic macular edema
08:16 - 08:24
Optimizing the treatment burden – Photon Study
08:25 - 08:42
Case I
08:43 - 09:00
Case II
Centenário
09:00 - 09:55 Session

Preventing and Treating Surgical Complications

09:00 - 09:06
Case
09:06 - 09:12
Case
09:12 - 09:18
Case
09:18 - 09:24
Case
09:24 - 09:30
Case
09:30 - 09:36
Case
09:36 - 09:42
Case
09:42 - 09:48
Case
09:48 - 09:54
Case
Centenário
09:55 - 10:03 Session

Vitelliform Deposits in Adults - Navigating Similarities and Distinctive Features with Multimodal Imaging and Functional Testing

Centenário
10:03 - 10:30 Break

Break

Centenário
10:30 - 10:55 Session

Fire Cases for Alexandra Miere

Centenário
10:55 - 11:20 Session

Secondary IOL implanation – Limitations and complications: from sweet dreams to nightmares

10:55 - 10:58
Yamane technique
10:58 - 11:01
Goretex technique
11:01 - 11:04
Scleral fixation technique
11:04 - 11:07
Hashtag technique
11:07 - 11:10
Iris Fixation technique
11:10 - 11:20
Discussion
Centenário
11:20 - 12:21 Session

Pros and Cons I

11:21 - 11:25
The use of complement inhibition can revolutionize the treatment of patients with geographic atrophy. - Yes
11:25 - 11:29
The use of complement inhibition can revolutionize the treatment of patients with geographic atrophy.- No
11:29 - 11:31
Discussion
11:31 - 11:35
Increasing the dosage of current intravitreal medications can be advantageous in the treatment of nAMD. - Yes
11:35 - 11:39
Increasing the dosage of current intravitreal medications can be advantageous in the treatment of nAMD. - No
11:39 - 11:41
Discussion
11:41 - 11:45
Multi-target therapies offer better durability in treating AMD than mono-target therapy with anti-VEGF.- Yes
11:45 - 11:49
Multi-target therapies offer better durability in treating AMD than mono-target therapy with anti-VEGF.- No
11:49 - 11:51
Discussion
11:51 - 11:55
Multi-target therapies offer better durability in treating DME than mono-target therapy with anti-VEGF. - Yes
11:55 - 11:59
Multi-target therapies offer better durability in treating DME than mono-target therapy with anti-VEGF. - No
11:59 - 12:01
Discussion
12:01 - 12:05
Biomarkers can potentially be employed to determine whether steroids or anti-VEGF agents are the more appropriate treatment for DME - Yes
12:05 - 12:09
Biomarkers can potentially be employed to determine whether steroids or anti-VEGF agents are the more appropriate treatment for DME - No
12:09 - 12:11
Discussion
12:11 - 12:15
Gene therapy is a promising therapy in real world practice - Yes
12:15 - 12:19
Gene therapy is a promising therapy in real world practice - No
12:19 - 12:20
Discussion
Centenário
12:21 - 12:30 Session

Choriocapillaris in OCT Angiography: A Biomarker of Age-Related Macular Degeneration?

Centenário
12:30 - 13:30 Break

Lunch

Centenário
13:30 - 14:48 Session

Artificial Intelligence and Retinal Imaging (hybrid session)

13:30 - 13:37
Basic concepts of AI and modeling from a clinical perspective
13:38 - 13:45
Considerations about ethics in AI in health care
13:46 - 13:53
Key considerations on ground truth for algorithm training and validation
13:54 - 14:08
Q&A
14:08 - 14:15
AI in clinical trial for retinal diseases
14:16 - 14:22
AI in geographic atrophy progression
14:23 - 14:30
AI-based Fluid monitor enhacing clinical decisions
14:31 - 14:48
Q&A
Centenário
14:48 - 15:50 Session

Age-related Macular Degeneration

14:48 - 14:56
Faricimab in age-related macular degeneration
14:56 - 15:04
Pegcetacoplan
15:04 - 15:12
Maximizing the durability – Pulsar Study
15:12 - 15:29
Case
15:29 - 15:46
Case
Centenário
15:50 - 16:20 Break

Break

Centenário
16:20 - 17:14 Session

Trauma and Retinal Detachment: the Good, the Bad and the Ugly

16:20 - 16:38
Case
16:38 - 16:56
Case
16:56 - 17:14
Case
Centenário
17:14 - 17:24 Session

Type 3 Macular Neovascularization in AMD - Origin, Diagnosis, and Masqueraders

Centenário
17:25 - 17:38 Session

Innovation in surgical fluidic with improved safety and effectiveness – Hypervit 20 000 cpm

Centenário
17:38 - 18:15 Session

Controversies in Vitreoretinal Surgery

17:38 - 17:44
Case
17:44 - 17:50
Case
17:50 - 17:56
Case
17:56 - 18:02
Case
18:02 - 18:08
Case
18:08 - 18:15
Case
Centenário
18:15 - 19:15 Symposium

Roche Symposium: A New Perspective in Treating wAMD and DME

18:15 - 18:18
Opening remarks
18:18 - 18:23
Far beyond VabysmoⓇ: Roche in Ophthalmology
18:23 - 18:32
VEGF-A + Ang-2 = a new logic for wAMD and DME
18:32 - 18:41
Unraveling the clinical trials puzzle
18:41 - 18:50
Late Breaking: the latest on VabysmoⓇ
18:50 - 18:59
Clinical cases on wAMD and DME
18:59 - 19:12
Expert discussion
19:12 - 19:15
Closing remarks and session closure
Centenário
07:55 - 08:00 Session

The best video, image and poster award.

Centenário
08:00 - 08:30 Session

Retinal vasculopathies in 2023

08:00 - 08:15
Case
08:15 - 08:30
Case
Centenário
08:30 - 09:30 Session

Nightmares in the operation room

08:30 - 08:36
Case
08:36 - 08:42
Case
08:42 - 08:48
Case
08:48 - 08:54
Case
08:54 - 09:00
Case
09:00 - 09:06
Case
09:06 - 09:12
Case
09:12 - 09:18
Case
09:18 - 09:24
Case
09:24 - 09:30
Case
Centenário
09:30 - 10:00 Session

Clinical Research and Future Treatments I

09:30 - 09:40
Nanovitreal techonology and approach to subretinal space
09:40 - 09:50
Dry AMD-Avacincatad Pegol
09:50 - 10:00
Sickle Cell Retinopathy: From Central Macular Involvement to Widefield OCT-Angiography
Centenário
10:00 - 10:30 Break

Break

Centenário
10:30 - 11:30 Session

Macular surgery: the useful, the futile and the dangerous

10:30 - 10:42
Autologous retinal transplant for macular holes. The past and future
10:42 - 10:50
Tractional myopic maculopathy
10:50 - 10:58
Vitreomacular traction
10:58 - 11:06
Submacular hemorrhage
11:06 - 11:14
Epiretinal membrane
11:14 - 11:30
Discussion
Centenário
11:30 - 12:30 Session

Retinaws

Centenário
12:30 - 13:30 Break

Lunch

Centenário
13:30 - 14:30 Session

Pros and Cons II

13:30 - 13:34
The preferred procedure for a large refractory macular hole - 1. Inverted ILM flap
13:34 - 13:38
The preferred procedure for a large refractory macular hole - 2. Subretinal fluid
13:38 - 13:42
The preferred procedure for a large refractory macular hole - 3. Autologous transplant
13:43 - 13:44
Discussion
13:45 - 13:49
Early x delayed surgery in myopic maculopathy - Early
13:49 - 13:53
Early x delayed surgery in myopic maculopathy - Late
13:53 - 13:55
Discussion
13:56 - 14:00
Silicone oil is toxic - Yes
14:00 - 14:04
Silicone oil is toxic - No
14:05 - 14:07
Discussion
14:08 - 14:12
Photobiomodulation is beneficial for dry AMD - Yes
14:12 - 14:16
Photobiomodulation is beneficial for dry AMD - No
14:16 - 14:18
Discussion
14:19 - 14:23
Floaterectomy is safe and beneficial in the management of vitreous opacities - Yes
14:23 - 14:27
Floaterectomy is safe and beneficial in the management of vitreous opacities - No
14:28 - 14:30
Discussion
Centenário
14:30 - 15:00 Session

Challenging Clinical Cases I

14:30 - 14:31
Case
14:32 - 14:35
Discussion
14:36 - 14:37
Case
14:38 - 14:41
Discussion
14:42 - 14:43
Case
14:44 - 14:47
Discussion
14:48 - 14:49
Case
14:50 - 14:53
Discussion
14:54 - 14:55
Case
14:56 - 15:00
Discussion
Centenário
15:00 - 15:30 Session

Retinal Inflammatory and Infectious Diseases

15:00 - 15:08
Update in imaging for noinfectious retinopathies
15:08 - 15:16
Update in imaging for infectious retinopathies
15:16 - 15:30
Discussion
Centenário
15:30 - 16:00 Break

Break

Centenário
16:00 - 16:35 Session

Retinal pediatric and genetic disease

16:00 - 16:08
Gene therapy in 2023
16:09 - 16:17
Luxturna: results and complications
16:18 - 16:34
Retinal pediatric panel
Centenário
16:35 - 17:15 Session

Ocular Oncology

16:35 - 16:42
Currrent management of vasoproliferative tumors
16:42 - 16:45
Discussion
16:45 - 16:52
Uveal melanoma in 2023
16:52 - 16:55
Discussion
16:55 - 17:02
Promising therapies of intraocular tumors
17:02 - 17:05
Discussion
17:05 - 17:12
Retinoblastoma in 2023
17:12 - 17:15
Discussion
Centenário
17:15 - 18:02 Session

Challenging clinical cases II

17:15 - 17:17
Case
17:17 - 17:21
Discussion
17:22 - 17:24
Case
17:24 - 17:28
Discussion
17:29 - 17:31
Case
17:31 - 17:35
Discussion
17:36 - 17:38
Case
17:38 - 17:42
Discussion
17:43 - 17:45
Case
17:45 - 17:49
Discussion
17:50 - 17:52
Case
17:52 - 17:56
Discussion
17:56 - 17:58
Case